Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Inhaled Treprostinil in Mild COPD
NCT06969573Phase 2Active, not recruiting
- Sponsor
- University of Alberta
- Start
- Jun 2025
- Primary completion
- Dec 2026
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of treprostinil in chronic obstructive pulmonary disease (COPD), sponsored by University of Alberta. Started Jun 2025; status: active, not recruiting.
02
Drugs
treprostinil
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT06969573.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06969573.